Mesoblast Limited
Mesoblast Limited (MEOBF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Mesoblast Limited (MEOBF), covering cash flow, earnings, and balance sheets.
Mesoblast Limited (MEOBF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Mesoblast Limited MEOBF financial performance.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $1.58M | $1.58M | $1.26M | $1.26M |
| Cost of Revenue | $3.28M | $3.28M | $10.84M | $10.84M |
| Gross Profit | -$1.70M | -$1.70M | -$9.58M | -$9.58M |
| Gross Profit Ratio | -$1.08 | -$1.08 | -$7.62 | -$7.62 |
| R&D Expenses | $10.32M | $10.32M | $6.35M | $6.35M |
| SG&A Expenses | $8.59M | $8.59M | $6.07M | $6.07M |
| Operating Expenses | $18.92M | $18.92M | $12.43M | $12.43M |
| Total Costs & Expenses | $22.20M | $22.20M | $23.26M | $23.26M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $537500.00 | $537500.00 | $436000.00 | $436000.00 |
| EBITDA | -$9.45M | -$9.45M | -$15.26M | -$15.26M |
| EBITDA Ratio | -$5.99 | -$5.99 | -$12.14 | -$12.14 |
| Operating Income | -$20.62M | -$20.62M | -$22.006M | -$22.006M |
| Operating Income Ratio | -$13.07 | -$13.07 | -$17.51 | -$17.51 |
| Other Income/Expenses (Net) | -$3.24M | -$3.24M | -$5.75M | -$5.75M |
| Income Before Tax | -$23.86M | -$23.86M | -$27.75M | -$27.75M |
| Income Before Tax Ratio | -$15.12 | -$15.12 | -$22.08 | -$22.08 |
| Income Tax Expense | $106000.00 | $106000.00 | $44500.00 | $44500.00 |
| Net Income | -$23.97M | -$23.97M | -$27.71M | -$27.71M |
| Net Income Ratio | -$15.19 | -$15.19 | -$22.04 | -$22.04 |
| EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.02 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $1.14B | $1.14B | $1.12B | $1.12B |
| Weighted Avg Shares Outstanding (Diluted) | $1.14B | $1.14B | $1.12B | $1.12B |
Over the past four quarters, Mesoblast Limited demonstrated steady revenue growth, increasing from $1.26M in Q3 2024 to $1.58M in Q2 2025. Operating income reached -$20.62M in Q2 2025, maintaining a consistent -1307% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$9.45M, reflecting operational efficiency. Net income rose to -$23.97M, with EPS at -$0.02. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan